Abstract
Cognitive dysfunction underpins some of the psychopathology of schizophrenia, as well as contributes to the patient's impaired social and vocational functioning and has now been recognized as an intrinsic dimension linked to functional outcome. Despite a general consensus on the capacity of antipsychotics to improve the psychopathology of schizophrenia, the dispute concerning their impact on cognitive function is constantly open.
We performed a selective review on the possible effects of antipsychotics, both of first and second generation, for a cognitive performance improvement. Other than the strict treatment, pharmacological effect and related aspects, such as dosage and pharmaco-induced brain structure modifications, placebo and practice effect issues have been considered. Interaction with specific cognitive interventions, such as remediation programs and enhancement treatments are discussed. On the basis of the current evidence-based findings, the hypothesis that cognition could be substantially influenced by antipsychotics has so far been demonstrated. Administering antipsychotic medications in an individually optimized manner seems to have the potential of improving cognitive aspects of schizophrenia, regardless of the kind of antipsychotic medication.Keywords: Medication management, antipsychotic agents, cognition, placebo, practice effect, cognitive remediation, cognitive enhancement
Current Psychopharmacology
Title:Antipsychotics and Cognitive Functioning: A Critical Review
Volume: 2
Author(s): Paolo Stratta, Ilaria Riccardi and Alessandro Rossi
Affiliation:
Keywords: Medication management, antipsychotic agents, cognition, placebo, practice effect, cognitive remediation, cognitive enhancement
Abstract: Cognitive dysfunction underpins some of the psychopathology of schizophrenia, as well as contributes to the patient's impaired social and vocational functioning and has now been recognized as an intrinsic dimension linked to functional outcome. Despite a general consensus on the capacity of antipsychotics to improve the psychopathology of schizophrenia, the dispute concerning their impact on cognitive function is constantly open.
We performed a selective review on the possible effects of antipsychotics, both of first and second generation, for a cognitive performance improvement. Other than the strict treatment, pharmacological effect and related aspects, such as dosage and pharmaco-induced brain structure modifications, placebo and practice effect issues have been considered. Interaction with specific cognitive interventions, such as remediation programs and enhancement treatments are discussed. On the basis of the current evidence-based findings, the hypothesis that cognition could be substantially influenced by antipsychotics has so far been demonstrated. Administering antipsychotic medications in an individually optimized manner seems to have the potential of improving cognitive aspects of schizophrenia, regardless of the kind of antipsychotic medication.Export Options
About this article
Cite this article as:
Stratta Paolo, Riccardi Ilaria and Rossi Alessandro, Antipsychotics and Cognitive Functioning: A Critical Review, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010037
DOI https://dx.doi.org/10.2174/2211556011302010037 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex
CNS & Neurological Disorders - Drug Targets Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews The α2δ Subunit and Absence Epilepsy: Beyond Calcium Channels?
Current Neuropharmacology An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Current Drug Targets Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease
Current Genomics Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics Characterisation of a Neural Teratogenicity Assay Based on Human ESCs Differentiation Following Exposure to Valproic Acid
Current Medicinal Chemistry Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Current Pharmaceutical Design Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets